{
    "clinical_study": {
        "@rank": "107637", 
        "arm_group": [
            {
                "arm_group_label": "Epsilonaminocaproic acid", 
                "arm_group_type": "Experimental", 
                "description": "One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo"
            }, 
            {
                "arm_group_label": "Placebo, Antifibrinolytic activity", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo: same IV volume as experimental arm"
            }
        ], 
        "brief_summary": {
            "textblock": "It is common practice to use antifibrinolytic agents before and during cardiopulmonary\n      bypass. They are not without side effects. The investigators want to show that there is no\n      proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary\n      bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass."
        }, 
        "brief_title": "Fibrinolysis Before Cardiopulmonary Bypass?", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pathologic Fibrinolysis", 
        "detailed_description": {
            "textblock": "Double-blind, placebo controlled, prospective study in two groups of 20 patients. Control\n      group (A) receives standard Epsilonaminocaproic acid treatment before cardiopulmonary bypass\n      (10 gr loading dose, and 1 gr/hr infusion), and second group (B) receives placebo. Before\n      start of Epsilonaminocaproic acid/placebo, D-Dimers and Thromboelastography are measured,\n      repeated just before full heparinization. After heparinization group A receives placebo, and\n      group B Epsilonaminocaproic acid."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All adult patients, undergoing first time sternotomy for Coronary artery bypass\n             grafting/Aortic valve replacement/aortic surgery\n\n        Exclusion Criteria:\n\n          -  Resternotomy, renal insufficiency, deep hypothermia, age < 18 yrs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981863", 
            "org_study_id": "Fibrinolysis"
        }, 
        "intervention": [
            {
                "arm_group_label": "Epsilonaminocaproic acid", 
                "description": "One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.", 
                "intervention_name": "Epsilonaminocaproic acid", 
                "intervention_type": "Drug", 
                "other_name": "Amicar"
            }, 
            {
                "arm_group_label": "Placebo, Antifibrinolytic activity", 
                "description": "Placebo administered in same volume as in experimental arm.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antifibrinolytic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cardiac surgery", 
            "cardiopulmonary bypass", 
            "fibrinolysis", 
            "thromboelastography", 
            "D-Dimers", 
            "antifibrinolytic agents"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "pieterva@stanford.edu", 
                "last_name": "Pieter Van der Starre, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford Hospital & Clinics"
            }, 
            "investigator": {
                "last_name": "Pieter Van der Starre, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Fibrinolysis Before Cardiopulmonary Bypass?", 
        "other_outcome": {
            "measure": "Fibrinolysis before cardiopulmonary bypass?", 
            "safety_issue": "No", 
            "time_frame": "8 months"
        }, 
        "overall_contact": {
            "email": "pieterva@stanford.edu", 
            "last_name": "Pieter Van der Starre, MD. PhD"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Pieter JA Van der Starre, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Significant increase of Di-dimer between preoperative value and value immediately before cardiopulmonary bypass in cardiac surgery patients.", 
            "measure": "Di-Dimer increase before cardiopulmonary bypass", 
            "safety_issue": "Yes", 
            "time_frame": "8 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981863"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Thromboelastography shows theoretically fibrinolysis if present, but the relationship with the level of increase of Di-dimers is unknown.", 
            "measure": "Value of Thromboelastography as monitor of fibrinolysis", 
            "safety_issue": "Yes", 
            "time_frame": "8 months"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}